vs
Side-by-side financial comparison of Bakkt Holdings, Inc. (BKKT) and Dianthus Therapeutics, Inc. (DNTH). Click either name above to swap in a different company.
Dianthus Therapeutics, Inc. is the larger business by last-quarter revenue ($284.0K vs $272.0K, roughly 1.0× Bakkt Holdings, Inc.). On growth, Dianthus Therapeutics, Inc. posted the faster year-over-year revenue change (-78.6% vs -100.0%). Over the past eight quarters, Dianthus Therapeutics, Inc.'s revenue compounded faster (-44.6% CAGR vs -98.2%).
Bakkt Holdings, Inc., headquartered in Alpharetta, Georgia and New York City, provides a software as a service (SaaS) and API platform for owning and trading cryptocurrency. Bakkt was founded, and is 55% owned, by Intercontinental Exchange (ICE), which also owns the New York Stock Exchange. Bakkt earns revenue from commissions for payments and purchases and sales of cryptocurrency.
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
BKKT vs DNTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $272.0K | $284.0K |
| Net Profit | — | $-64.4M |
| Gross Margin | — | — |
| Operating Margin | — | -24486.3% |
| Net Margin | — | -22687.3% |
| Revenue YoY | -100.0% | -78.6% |
| Net Profit YoY | -344.6% | -126.6% |
| EPS (diluted) | — | $-1.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $272.0K | $284.0K | ||
| Q3 25 | $-50.0K | $396.0K | ||
| Q2 25 | $577.9M | — | ||
| Q1 25 | $1.1B | $1.2M | ||
| Q4 24 | $1.7B | $1.3M | ||
| Q3 24 | $328.4M | $2.2M | ||
| Q2 24 | $509.9M | $1.9M | ||
| Q1 24 | $854.6M | $874.0K |
| Q4 25 | — | $-64.4M | ||
| Q3 25 | $-14.9M | $-36.8M | ||
| Q2 25 | $-14.7M | — | ||
| Q1 25 | $7.7M | $-29.5M | ||
| Q4 24 | $-19.2M | $-28.4M | ||
| Q3 24 | $-2.9M | $-25.2M | ||
| Q2 24 | $-16.4M | $-17.6M | ||
| Q1 24 | $-8.2M | $-13.7M |
| Q4 25 | — | -24486.3% | ||
| Q3 25 | 50526.0% | -10173.7% | ||
| Q2 25 | -3.2% | — | ||
| Q1 25 | -1.7% | -2852.7% | ||
| Q4 24 | -0.2% | -2406.9% | ||
| Q3 24 | -7.7% | -1376.6% | ||
| Q2 24 | -4.3% | -1191.8% | ||
| Q1 24 | -3.7% | -2041.6% |
| Q4 25 | — | -22687.3% | ||
| Q3 25 | 29836.0% | -9284.1% | ||
| Q2 25 | -2.5% | — | ||
| Q1 25 | 0.7% | -2537.5% | ||
| Q4 24 | -1.1% | -2144.8% | ||
| Q3 24 | -0.9% | -1159.0% | ||
| Q2 24 | -3.2% | -945.1% | ||
| Q1 24 | -1.0% | -1573.0% |
| Q4 25 | — | $-1.53 | ||
| Q3 25 | $-1.15 | $-0.97 | ||
| Q2 25 | $-2.16 | — | ||
| Q1 25 | $1.13 | $-0.82 | ||
| Q4 24 | $-2.99 | $-0.76 | ||
| Q3 24 | $-0.45 | $-0.74 | ||
| Q2 24 | $-2.67 | $-0.51 | ||
| Q1 24 | $-1.86 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.2M | $404.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $112.8M | $493.4M |
| Total Assets | $162.8M | $530.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.2M | $404.3M | ||
| Q3 25 | $58.3M | $402.6M | ||
| Q2 25 | $43.5M | — | ||
| Q1 25 | $23.0M | $263.2M | ||
| Q4 24 | $39.0M | $275.2M | ||
| Q3 24 | $29.0M | $281.1M | ||
| Q2 24 | $47.5M | $360.7M | ||
| Q1 24 | $56.6M | $377.0M |
| Q4 25 | $112.8M | $493.4M | ||
| Q3 25 | $114.4M | $546.5M | ||
| Q2 25 | $35.3M | — | ||
| Q1 25 | $44.1M | $328.6M | ||
| Q4 24 | $33.9M | $352.5M | ||
| Q3 24 | $50.5M | $337.9M | ||
| Q2 24 | $47.8M | $358.2M | ||
| Q1 24 | $57.0M | $372.7M |
| Q4 25 | $162.8M | $530.9M | ||
| Q3 25 | $258.3M | $577.4M | ||
| Q2 25 | $190.1M | — | ||
| Q1 25 | $176.3M | $348.6M | ||
| Q4 24 | $269.4M | $374.0M | ||
| Q3 24 | $1.2B | $354.2M | ||
| Q2 24 | $1.2B | $369.0M | ||
| Q1 24 | $1.6B | $382.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-153.4M | $-47.0M |
| Free Cash FlowOCF − Capex | — | $-47.1M |
| FCF MarginFCF / Revenue | — | -16591.9% |
| Capex IntensityCapex / Revenue | — | 48.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-132.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-153.4M | $-47.0M | ||
| Q3 25 | $-46.7M | $-30.6M | ||
| Q2 25 | $5.4M | — | ||
| Q1 25 | $-101.3M | $-27.6M | ||
| Q4 24 | $31.4M | $-27.4M | ||
| Q3 24 | $-25.1M | $-21.3M | ||
| Q2 24 | $-65.9M | $-14.5M | ||
| Q1 24 | $38.4M | $-14.9M |
| Q4 25 | — | $-47.1M | ||
| Q3 25 | — | $-30.6M | ||
| Q2 25 | $5.3M | — | ||
| Q1 25 | $-101.4M | $-27.7M | ||
| Q4 24 | $31.1M | $-27.5M | ||
| Q3 24 | $-25.6M | $-21.3M | ||
| Q2 24 | $-66.4M | $-14.5M | ||
| Q1 24 | $36.6M | $-15.0M |
| Q4 25 | — | -16591.9% | ||
| Q3 25 | — | -7717.2% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | -9.4% | -2377.8% | ||
| Q4 24 | 1.8% | -2072.0% | ||
| Q3 24 | -7.8% | -980.3% | ||
| Q2 24 | -13.0% | -780.7% | ||
| Q1 24 | 4.3% | -1713.2% |
| Q4 25 | — | 48.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | 2.1% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.1% | 0.9% | ||
| Q1 24 | 0.2% | 3.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -13.14× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
